Balance Sheet
Accounts PayablesAccumulated ExpensesCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Total Non-Current Liabilities: 2023-2025

  • Zhengye Biotechnology Holding's Total Non-Current Liabilities was N/A to $649,788 in Q2 2025 from the same period last year, while for Jun 2025 it was $649,788, marking a year-over-year change of. This contributed to the annual value of $658,000 for FY2024, which is 55.21% down from last year.
  • As of Q2 2025, Zhengye Biotechnology Holding's Total Non-Current Liabilities stood at $649,788, which was down 2.76% from $668,235 recorded in Q4 2024.
  • Zhengye Biotechnology Holding's 5-year Total Non-Current Liabilities high stood at $1.4 million for Q4 2023, and its period low was $649,788 during Q2 2025.
  • Its 3-year average for Total Non-Current Liabilities is $920,030, with a median of $668,235 in 2024.
  • Data for Zhengye Biotechnology Holding's Total Non-Current Liabilities shows a maximum YoY plummeted of 53.66% (in 2024) over the last 5 years.
  • Zhengye Biotechnology Holding's Total Non-Current Liabilities (Quarterly) stood at $1.4 million in 2023, then tumbled by 53.66% to $668,235 in 2024, then reached $649,788 in 2025.
  • Its last three reported values are $649,788 in Q2 2025, $668,235 for Q4 2024, and $1.4 million during Q4 2023.